ASEAN Common Technical Requirements: What They Do (and Don't Do) in Thailand

Supplement brands that have already navigated a market entry somewhere else in ASEAN often arrive in Thailand assuming most of the regulatory work is already done. The ASEAN Common Technical Requirements, built for exactly this kind of cross-border harmonization, do lighten the documentation load. What they do not do is substitute for Thai FDA approval, and the gap between those two facts is where a lot of otherwise well-prepared applications lose time. Understanding precisely where that gap sits, rather than assuming it does not exist, is the single most useful thing a manufacturer can do before committing to a Thailand launch timeline built on ASEAN documentation alone.

What the ASEAN harmonization framework actually establishes

ASEAN built its harmonization structure for traditional medicines and health supplements specifically, not as an afterthought bolted onto pharmaceutical harmonization. The ASEAN Agreement on Traditional Medicines and Health Supplements, signed in 2004 and in force from 2011, commits member states, Thailand included, to align their national regulatory frameworks toward a shared set of common technical requirements.

Those requirements, known as the ACTR, set baseline standards across four areas: product composition and permitted claims, safety and efficacy data, labeling, and GMP. The intent behind ACTR was straightforward: reduce the degree to which a manufacturer has to build an entirely separate dossier for each ASEAN market, since much of the underlying technical substance should be reusable across borders.

The word that matters most here is baseline. ACTR sets a floor, and every member state retains full authority to layer national requirements on top of it. Thailand has done exactly this in several places that carry real weight: the positive-list health claims framework under MOPH No. 447, and the vitamin and mineral maximum levels under MOPH No. 448. A dossier that satisfies the ACTR baseline in full can still fall short of what Thai FDA specifically requires, because Thailand's own rules go further than the regional floor in these areas.

Where ACTR-format documentation genuinely transfers

The alignment between ACTR and Thai requirements is real, but it is narrower and more specific than "harmonized" tends to suggest, and it is worth being precise about where it actually holds.

On GMP, the ACTR standard for health supplement manufacturing tracks closely with Thailand's own MOPH No. 420 equivalence standard. A manufacturer already holding a recognized food-safety management system certification prepared for ASEAN compliance purposes is likely already positioned to satisfy Thailand's GMP evidence requirement as well, without rebuilding that evidence from scratch.

Safety documentation carries over in a similar way. ACTR-format safety data, including ingredient safety assessments and toxicological information, is generally acceptable to Thai FDA as part of a product approval submission. The documents do not need a full reformat, though any Thai-language translation requirements attached to specific sections still apply regardless of the original format.

Labeling structure is broadly compatible but not complete. A label built to ACTR specifications will already cover most of the required elements, but it will be missing Thailand-specific additions that ACTR was never designed to include: the Thai food serial number, the mandatory Thai-language warning statement, and the category descriptor ผลิตภัณฑ์เสริมอาหาร as part of the product name.

Ingredient composition is where the ACTR baseline runs out fastest. ACTR provides a reference framework for permitted ingredients and levels, but in Thailand, No. 448's maximum levels govern approval regardless of what ACTR itself would allow. Wherever the two frameworks diverge, Thai FDA's own limits are the ones that decide the outcome, and any conflict has to be resolved against the Thai standard specifically.

Why an ASEAN approval elsewhere does not shortcut Thailand

There is no mutual recognition agreement anywhere in ASEAN covering health supplements. A notification or registration approval already secured in Singapore, Malaysia, or any other member state does not grant, accelerate, or in any way substitute for Thai FDA approval under Thailand's own Food Act.

This is one of the more common misconceptions among supplement brands that have already cleared one ASEAN market and assume the regulatory groundwork simply carries over. It does not, because ACTR harmonization was built around documentation structure and technical standards, not reciprocal approval between governments. A product already registered as a health supplement in Singapore still needs a complete, standalone Thai FDA product approval application: a genuinely Thai-language label, GMP evidence that meets Thailand's own standard, an Orr.7 licensed importer in place, and every intended health claim assessed against MOPH No. 447 on its own terms.

The regional context behind Thailand's stricter national rules

It is worth understanding why Thailand has chosen to build national requirements on top of the ACTR floor rather than simply adopting the regional baseline outright. Thailand's food regulatory apparatus, administered through Thai FDA under the Food Act B.E. 2522, predates the ACTR harmonization effort by decades and already had an established domestic framework for food supplements when the ASEAN agreement came into force in 2011. Rather than replacing that domestic framework, Thailand layered ACTR compliance on top of it where the two aligned, and retained its own stricter rules where domestic policy considerations, such as the positive-list approach to health claims or specific vitamin and mineral ceilings, took precedence. This pattern is not unique to Thailand within ASEAN; several member states retain national requirements that exceed the ACTR floor in areas they consider higher priority, which is precisely why a genuinely harmonized single ASEAN dossier does not yet exist for health supplements the way it increasingly does for some pharmaceutical categories.

For a manufacturer building a multi-country ASEAN launch plan, this means the ACTR baseline is best treated as the starting point for a shared core dossier, with a country-specific supplement layered on top for each market. Thailand's supplement is larger than some neighboring markets because of the claims and composition rules described above, but the underlying GMP and safety data package built to ACTR standards remains the efficient starting point rather than something to set aside.

Using ACTR groundwork without over-relying on it

For brands that already have ACTR-format documentation from another ASEAN market, the useful exercise is sorting what adapts directly into the Thai submission from what still needs rebuilding. GMP and safety evidence typically transfer with only light adaptation. The label needs Thailand-specific elements added rather than translated. The health claims need a full remapping against MOPH No. 447, since ACTR compatibility says nothing about whether a given claim survives Thailand's positive list. An ASEAN track record reduces the preparation burden where the underlying technical work already meets a compatible standard, but it does not shorten the Thai review timeline itself. DeeMED Consulting works through exactly this gap analysis as part of our Thai FDA dietary supplement registration support, identifying what ACTR-format documentation carries over cleanly and what needs to be rebuilt specifically for the Thai submission.